Two new drugs for rare diseases in Germany will make their debut at the 3rd World Expo

at the upcoming 3rd China International Import Expo in Shanghai, Grigg Ingham, a large German multinational, will "make his debut" on two new drugs for the treatment of rare diseases.
Generalized pustules psoriasis (GPP) is an extremely rare skin disease in which patients develop many sterile pustules in various areas of the body, with sudden fever, chills and painful skin lesions, which are not only extremely painful, but may also be accompanied by life-threatening organ failure and infectious complications. Spesolimab, developed by Grigg Ingham, is an innovative monoclonal antibody drug that is being studied in Phase II clinical studies and is expected to be effective in the treatment of GPP. The drug is also the first of its kind in the world to include China in the field of rare diseases developed simultaneously worldwide, supported by Grigg Ingham's "Key in China" project.
Nidanib (Vegat) is the world's first and currently only approved drug for the treatment of systemic sclerosis (sC-ILD), a rare disease that causes "mask faces" that can cause breathing difficulties in patients with visceral fibrosis as the disease progresses. Although there is currently no cure for scurt disease, this rare and innovative drug can help patients fight and co-incur the disease. The drug's adaptation was approved in China in June this year, just 1.5 months after it was approved by the European Union.
in the Public Health Anti-Epidemic Zone, Blainger Ingeham will demonstrate the latest developments in its research and development in the field of neo-coronary pneumonia, including an oversized new coronavirus and antibody model, TRPC6 inhibitor BI-764198 treatment of new coronavirus-induced acute respiratory distress syndrome Phase II clinical trials. Since the outbreak of new coronary pneumonia, Grigg Ingeham, in addition to donating cash and medicines to China, has also actively participated in the research and development of a number of new drugs, carried out in-body trials using ammonia hydrochloride for the effects of the new coronavirus, and supported a real-world study of the treatment of new coronavirus pneumonia initiated by Wuhan University Central South Hospital.